Format

Send to

Choose Destination
Cell Cycle. 2017 Jan 2;16(1):19-20. doi: 10.1080/15384101.2016.1247568. Epub 2016 Oct 20.

Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?

Author information

1
a Department of Medicine , Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston , MA , USA.

KEYWORDS:

ALK; Anaplastic lymphoma kinase; STAT3; acquired resistance; alectinib; ceritinib; crizotinib; lung cancer

PMID:
27764548
PMCID:
PMC5270524
DOI:
10.1080/15384101.2016.1247568
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center